5NRA Stock Overview
A clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Nanobiotix S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €3.24 |
| 52 Week High | €7.45 |
| 52 Week Low | €3.24 |
| Beta | 1.4 |
| 11 Month Change | -20.20% |
| 3 Month Change | -28.32% |
| 1 Year Change | -34.68% |
| 33 Year Change | -54.69% |
| 5 Year Change | n/a |
| Change since IPO | -75.82% |
Recent News & Updates
Recent updates
Shareholder Returns
| 5NRA | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -9.5% | -0.2% | 0.8% |
| 1Y | -34.7% | -16.9% | 9.1% |
Return vs Industry: 5NRA underperformed the German Biotechs industry which returned -17.2% over the past year.
Return vs Market: 5NRA underperformed the German Market which returned 8.5% over the past year.
Price Volatility
| 5NRA volatility | |
|---|---|
| 5NRA Average Weekly Movement | 7.0% |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 5NRA's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 5NRA's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 110 | Laurent Levy | www.nanobiotix.com |
Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand.
Nanobiotix S.A. Fundamentals Summary
| 5NRA fundamental statistics | |
|---|---|
| Market cap | €157.86m |
| Earnings (TTM) | -€33.47m |
| Revenue (TTM) | €42.20m |
3.7x
P/S Ratio-4.7x
P/E RatioIs 5NRA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 5NRA income statement (TTM) | |
|---|---|
| Revenue | €42.20m |
| Cost of Revenue | €0 |
| Gross Profit | €42.20m |
| Other Expenses | €75.68m |
| Earnings | -€33.47m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.71 |
| Gross Margin | 100.00% |
| Net Profit Margin | -79.31% |
| Debt/Equity Ratio | -204.3% |
How did 5NRA perform over the long term?
See historical performance and comparison